Literature DB >> 3674962

Neutrophil locomotion and serum chemotactic and chemokinetic activities in pustulosis palmoplantaris compared with psoriasis.

A Lundin1, L Håkansson, G Michaëlsson, P Venge.   

Abstract

Twenty patients with palmoplantar pustulosis (PPP) and 21 patients with psoriasis were compared with respect to the chemotactic response and random migration of their neutrophils (PMNs) and to the chemotactic and chemokinetic activities of their serum. The Boyden chamber technique was used. Compared with the reference group, the PPP neutrophils showed a significant decrease in random migration (p = 0.036) and chemotactic response to casein (p = 0.031), but not to zymosan-activated serum. The psoriasis PMNs had normal chemotactic response, but decreased random migration (p = 0.001). The chemokinetic effects of serum from PPP and psoriatic patients on normal neutrophils were increased (for PPP, p = 0.019 and for psoriasis p = 0.024). The chemokinetic activity of the heated sera was decreased and inversely correlated to the serum level of IgA in both disorders (PPP, p = 0.021; psoriasis, p = 0.013). The chemotactic activity of serum on normal PMNs was decreased in both conditions (PPP, p = 0.001; psoriasis, p = 0.047); this was due to the presence of chemotactic factor inhibitors in 34% of the sera. It seems likely that the high chemokinetic effect of serum both from the PPP and from the psoriasis patients compensates for the slightly low or normal migratory activity of neutrophils from these patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3674962     DOI: 10.1007/bf00412624

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  25 in total

1.  Is chemotactic activity of polymorphonuclear leukocytes increased in psoriasis?

Authors:  A Langner; T P Chorzelski; M Fraczykowska; S Jabłońska
Journal:  Arch Dermatol Res       Date:  1983       Impact factor: 3.017

2.  Serum-mediated stimulation and inhibition of neutrophil locomotion in sarcoidosis.

Authors:  B Schmekel; L Håkansson; R Hällgren; G Stålenheim; P Venge
Journal:  Eur J Respir Dis       Date:  1984-11

3.  Partial characterization and identification of chemokinetic factors in serum.

Authors:  L Håkansson; P Venge
Journal:  Scand J Immunol       Date:  1983-12       Impact factor: 3.487

4.  Neutrophil polymorphonuclears, mediators and the pathogenesis of psoriasis.

Authors:  M W Greaves
Journal:  Br J Dermatol       Date:  1983-07       Impact factor: 9.302

5.  In vivo mobilization of polymorphonuclear leukocytes in psoriasis: relationship to clinical parameters and serum inhibitory factors.

Authors:  M Tigalonowa; W Glinski; S Jablonska
Journal:  J Invest Dermatol       Date:  1983-07       Impact factor: 8.551

6.  Neutrophil studies in psoriatics: in vivo migration, phagocytosis and bacterial killing.

Authors:  L Dubertret; C Lebreton; R Touraine
Journal:  J Invest Dermatol       Date:  1982-08       Impact factor: 8.551

7.  Increased in vivo secretory activity of neutrophil granulocytes in patients with psoriasis and palmoplantar pustulosis.

Authors:  A Lundin; L Håkansson; R Hällgren; G Michaëlsson; P Venge
Journal:  Arch Dermatol Res       Date:  1985       Impact factor: 3.017

8.  Neutrophil and monocyte chemotaxis in pustulosis palmo-plantaris and pustular psoriasis.

Authors:  T Ternowitz; K Thestrup-Pedersen
Journal:  Br J Dermatol       Date:  1985-11       Impact factor: 9.302

9.  Altered polymorphonuclear leukocyte responses in psoriasis: chemotaxis and degranulation.

Authors:  W C Preissner; J M Schröder; E Christophers
Journal:  Br J Dermatol       Date:  1983-07       Impact factor: 9.302

10.  IgA-associated inhibition of polymorphonuclear leukocyte chemotaxis in neutrophilic dermatoses.

Authors:  J M Schröder; B Szperalski; C J Koh; E Christophers
Journal:  J Invest Dermatol       Date:  1981-12       Impact factor: 8.551

View more
  1 in total

Review 1.  Autoinflammatory pustular neutrophilic diseases.

Authors:  Haley B Naik; Edward W Cowen
Journal:  Dermatol Clin       Date:  2013-06-02       Impact factor: 3.478

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.